NTLA
INTELLIA THERAPEUTICS, INC.Marquee-fund ownership over time
This quarter's activity
New positions opened
Current holders
Sorted by tenure (longest first)| Fund | First disclosed | Held | Entry price | Latest close | Return on entry |
|---|---|---|---|---|---|
| Citadel Advisors | Q3 2024(8Q snapshot) | 7Q | $22 | $13 | -41% |
| Two Sigma Investments | Q3 2024(8Q snapshot) | 7Q | $22 | $13 | -41% |
| Millennium Management | Q3 2024(8Q snapshot) | 7Q | $22 | $13 | -41% |
| D.E. Shaw | Q4 2024(8Q snapshot) | 6Q | $15 | $13 | -16% |
| AQR Capital Management | Q1 2025(8Q snapshot) | 5Q | $11 | $13 | +19% |
| Point72 Asset Management re-entered | Q4 2025(8Q snapshot) | 2Q | $8.70 | $13 | +46% |
“Return on entry” is the price-only move from the fund's first disclosure to today — it ignores any adds, trims, or dividends. A fund that built its position over multiple quarters has a true cost basis somewhere between entry price and latest close; this figure is the upper bound.
Past holders
Funds that exited at some point| Fund | Last entry | Exited | Entry → Exit | Return |
|---|---|---|---|---|
| Bridgewater Associates 3× in & out | Q1 2026 | Q2 2026 | → $14 | +15% |
| Renaissance Technologies 3× in & out | Q3 2025 | Q2 2026 | → $13 | +19% |
| Viking Global Investors | Q3 2021 | Q3 2023 | → $39 | -75% |
| Coatue Management | Q4 2021 | Q2 2022 | → $46 | -65% |
Insider activity
Form 4 — officers, directors, 10%+ ownersFiled within two business days of each transaction by anyone with material insider status at Intellia Therapeutics, Inc.. Pair with the holders table above as a sanity check: heavy insider buying alongside marquee-fund accumulation is the strongest accumulation signal; heavy insider selling alongside fund exits is the strongest distribution signal.
30d / 90d windows measured from Mar 3, 2026 — the most recent Form 4 on file — not from today.
- Form 40001193125-26-088269Mar 3, 2026
- Form 40001193125-26-088260Mar 3, 2026
- Form 40001193125-26-088258Mar 3, 2026
- Form 40001193125-26-088254Mar 3, 2026
- Form 40001193125-26-088251Mar 3, 2026
- Form 40001193125-26-088241Mar 3, 2026
- Form 40001193125-26-088236Mar 3, 2026
- Form 40001193125-26-006294Jan 7, 2026
- Form 40001193125-26-006292Jan 7, 2026
- Form 40001193125-26-006291Jan 7, 2026
- Form 40001193125-26-006288Jan 7, 2026
- Form 40001193125-26-006283Jan 7, 2026
- Form 40001193125-26-006278Jan 7, 2026
- Form 40001193125-26-006275Jan 7, 2026
- Form 40001193125-26-006264Jan 7, 2026
Fundamentals
XBRL · INTELLIA THERAPEUTICS, INC.Annual figures sourced directly from INTELLIA THERAPEUTICS, INC.'s 10-K / 10-Q filings via SEC EDGAR XBRL. Latest fiscal year and the year-over-year change, with up to ten years of history.
Recent SEC filings
10-K · 10-Q · 8-K · 13D/G · proxyThe most recent material filings for Intellia Therapeutics, Inc. — earnings, material events, ownership disclosures, proxy statements. Form 4 insider activity is shown in the panel above.
- 10-QQuarterly reportMay 11, 2026
- 8-KMaterial eventMay 11, 2026
- 8-KMaterial eventApr 30, 2026
- DEF 14AProxy statementApr 30, 2026
- 8-KMaterial eventApr 27, 2026
- 8-KMaterial eventApr 10, 2026
- 8-KMaterial eventMar 2, 2026
- 10-KAnnual reportFeb 26, 2026
- 8-KMaterial eventFeb 26, 2026
- 8-KMaterial eventJan 27, 2026
- 8-KMaterial eventJan 9, 2026
- 8-KMaterial eventNov 10, 2025
- 10-QQuarterly reportNov 6, 2025
- 8-KMaterial eventNov 6, 2025
- 8-KMaterial eventOct 29, 2025
Trade history
Every open→close lifecycle across tracked funds| Fund | Open date | Close date | Open price | Close price / current | Return |
|---|---|---|---|---|---|
| Point72 Asset Management | Q2 2026 | open | $14 | $13 | -7% |
| Bridgewater Associates | Q1 2026 | Q2 2026 | $12 | $14 | +15% |
| Point72 Asset Management | Q4 2025 | Q1 2026 | $8.70 | $12 | +40% |
| Renaissance Technologies | Q3 2025 | Q2 2026 | $11 | $13 | +19% |
| AQR Capital Management | Q1 2025 | open | $11 | $13 | +19% |
| Renaissance Technologies | Q1 2025 | Q2 2025 | $9.64 | $7.88 | -18% |
| D.E. Shaw | Q4 2024 | open | $15 | $13 | -16% |
| Citadel Advisors | Q3 2024 | open | $22 | $13 | -41% |
| Two Sigma Investments | Q3 2024 | open | $22 | $13 | -41% |
| Millennium Management | Q3 2024 | open | $22 | $13 | -41% |
| Renaissance Technologies | Q3 2024 | Q4 2024 | $21 | $16 | -25% |
| Bridgewater Associates | Q1 2023 | Q2 2023 | $41 | $43 | +5% |
| Bridgewater Associates | Q2 2022 | Q3 2022 | $49 | $66 | +35% |
| Coatue Management | Q4 2021 | Q2 2022 | $132 | $46 | -65% |
| Viking Global Investors | Q3 2021 | Q3 2023 | $153 | $39 | -75% |
- Covers only the 27 marquee funds tracked here, not the full institutional universe. A “0 holders” reading does not mean unowned.
- Heavy funds (Renaissance Technologies, Citadel Advisors, Soros Fund Management, Two Sigma Investments, D.E. Shaw, AQR Capital Management, Millennium Management, Point72 Asset Management) use 8-quarter snapshots, so their pre-2024 history is missing.
- “Current” reflects each fund's most recent 13F — filings lag the actual trade by up to 45 days; positions shown may have changed since.
- Cost = price at the entry filing date. Re-entered positions show the most recent open lot.
- Options, ADRs, and unmapped CUSIPs are excluded from the follower-backtest pipeline that produces these snapshots, so certain holding types won't appear here.